Vertaling van "stage for further " (Nederlands → Frans) :

Considerable attention was focused in 2007 on increased cooperation on the part of the FAMHP with the ethics committees, with the following results: ●● An interactive website with a web application that makes possible the “simple” management of communication actions between the different ethics committees, the FAMHP, the sponsors and researchers, and also monitors the different stages in the evaluation of each application by the ethics committees ●● Systematic consultation for the more complex scientific applications ●● Further optimisation of the functioning of
Considerable attention was focused in 2007 on increased cooperation on the part of the FAMHP with the ethics committees, with the following results: ●● An interactive website with a web application that makes possible the “simple” management of communication actions between the different ethics committees, the FAMHP, the sponsors and researchers, and also monitors the different stages in the evaluation of each application by the ethics committees ●● Systematic consultation for the more complex scientific applications ●● Further optimisation of the functioning of

The late-stage pipeline is also progressing quickly: European regulatory approval expected soon for QAB149 (COPD), while further positive Phase III data presented in September 2009 reaffirmed the potential of FTY720 (MS).
Le pipeline de médicaments en phase ultime de développement progresse également avec rapidité. En effet, l’homologation de QAB149 (BPCO) est attendue sous peu tandis que de nouveaux résultats positifs de phase III présentés en septembre 2009 ont confirmé le potentiel de FTY720 (SEP).

The continued strong growth in biosimilars was led by products such as Omnitrope, which has made steady gains against originator growth hormone deficiency treatments, as well as the launches of oncology indications of Binocrit (epoetin alfa) and Zarzio (filgrastim), setting the stage for further expansion of Sandoz’s position as the biosimilars market leader.
La forte progression continue des biosimilaires a été menée par des produits comme Omnitrope, qui na cessé de gagner du terrain face aux traitements originaux du déficit de l’hormone de croissance ainsi que par les lancements des indications oncologiques de Binocrit (époétine alfa) et Zarzio (filgrastim). Ainsi la voie est ouverte pour permettre à Sandoz de conforter sa position de leader du marché des biosimilaires.